Understanding the metabolic vulnerabilities of cancer cells has long been a cornerstone of cancer biology. A critical metabolite in this landscape is acetyl-coenzyme A (acetyl-CoA), a pivotal molecule involved in energy metabolism, lipid synthesis, and epigenetic modulation. Elevated levels of acetyl-CoA have been documented to drive cancer metastasis, yet the precise source of this metabolite within the tumor microenvironment remained elusive. The innovative work spearheaded by Shen and colleagues uncovers that TAMs secrete acetate, a key precursor metabolite, which tumor cells avidly take up to maintain high intracellular acetyl-CoA levels critical for metastatic behavior.

This discovery uncovers a previously unappreciated metabolic symbiosis: HCC tumor cells secrete lactate into their surrounding environment, which paradoxically activates a metabolic pathway in TAMs characterized by lipid peroxidation and the enzymatic activity of aldehyde dehydrogenase 2 (ALDH2). This activation triggers TAMs to convert lipid peroxidation products into acetate, which they then release back into the microenvironment. In essence, HCC cells manipulate TAMs to produce a vital fuel—acetate—creating a reciprocal loop that supports tumor aggressiveness.

Delving deeper into the molecular mechanisms, the study highlights ALDH2 as a linchpin enzyme driving the acetate-producing capability of TAMs. Lipid peroxidation generates reactive aldehydes that can be detoxified and metabolized into acetate by ALDH2. By pharmacologically inhibiting ALDH2 or blocking lipid peroxidation processes within TAMs, the researchers effectively curtailed acetate production. Remarkably, this intervention suppressed the migratory and invasive capabilities of HCC cells in vitro, underscoring the potential therapeutic value of targeting this metabolic axis to restrain cancer dissemination.

The researchers then translated these in vitro findings into an orthotopic HCC mouse model, employing genetic ablation to selectively eliminate ALDH2 within TAMs. This genetic intervention yielded profound reductions in acetate availability within tumor cells and correspondingly led to a marked decrease in lung metastases. These in vivo results validate the pivotal role of TAM-derived acetate in facilitating metastatic spread and potentiate ALDH2 inhibition as a promising anti-metastatic strategy.

This study elegantly bridges the gap between metabolic biochemistry and tumor immunology by portraying TAMs not merely as passive bystanders or immune effectors but as active metabolic accomplices that nurture cancer progression. The metabolic plasticity of TAMs, particularly their ability to harness lipid peroxidation pathways to generate acetate, reveals a layer of complexity in tumor-stroma interactions that had previously gone unappreciated.

The implications of these findings extend beyond HCC, potentially informing understanding in other malignancies where macrophage infiltration and acetate metabolism intersect. Tumors are known to exploit local microenvironmental factors, including immune cells and metabolic substrates, to thrive and metastasize. Un covering the metabolic dialogue that enables such exploitation offers innovative angles for therapeutic intervention, particularly in combating metastasis, the primary cause of cancer mortality.

It is also significant that the study positions lactate, a common metabolic byproduct of cancer cells’ glycolytic metabolism, as a key mediator orchestrating acetate production in TAMs. This recasts lactate from a mere waste product to a signaling molecule within the tumor milieu, modulating immune cell metabolism to favor cancer progression. Such insights contribute to a growing appreciation of lactate’s dual role as a metabolic substrate and an immunomodulatory signal in cancer.

Targeting ALDH2 enzymatic activity emerges as a compelling therapeutic route. Given ALDH2’s role in detoxifying lipid peroxidation aldehydes and facilitating acetate production, inhibiting this enzyme may cripple the metabolic support TAMs provide to tumor cells. This therapeutic approach could synergize with existing treatments, potentially mitigating metastatic dissemination and improving patient outcomes.

Moreover, these findings prompt a re-evaluation of how tumor microenvironments are conceptualized—highlighting the dynamic metabolic interdependencies between cancer cells and surrounding stromal and immune elements. Recognizing that immune cells such as TAMs can serve as reservoirs and factories for critical metabolites may revolutionize strategies to disrupt tumor metabolism at multiple fronts.

The complexity of lipid peroxidation pathways in TAMs, implicated in this acetate production, also invites further investigation. Understanding the specific lipid substrates undergoing peroxidation, and the signals triggering this process in TAMs when exposed to tumor-derived lactate, could reveal additional molecular targets to disrupt this metabolic crosstalk.

In light of these insights, future research may explore how modulation of microenvironmental acetate levels impacts epigenetic modifications in cancer cells, given acetyl-CoA’s pivotal role as a substrate for histone acetylation. This could open avenues linking metabolic regulation by TAMs to the epigenetic reprogramming that underlies metastatic competence.

Equally, the study underscores the need to consider cellular heterogeneity within the tumor microenvironment. TAM subpopulations with varying metabolic profiles might differentially contribute to acetate production and tumor support, suggesting tailored interventions might be required for maximal therapeutic efficacy.

In conclusion, the discovery that tumor-associated macrophages act as an acetate reservoir to drive hepatocellular carcinoma metastasis unveils a sophisticated metabolic alliance that enables aggressive cancer behavior. By dissecting the lactate-induced activation of lipid peroxidation and ALDH2 pathways in TAMs, this research provides a mechanistic understanding that not only advances fundamental cancer biology but also signals new frontiers for therapeutic innovation targeting the metabolic ecosystems supporting metastasis.

Subject of Research: Tumor-associated macrophages as metabolic contributors to hepatocellular carcinoma metastasis through acetate production.

Article Title: Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis.

Article References:
Shen, L., Wang, S., Gao, C. et al. Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01393-9

Image Credits: AI Generated

The Y chromosome, a defining genetic element for biological males, is known to gradually disappear from certain somatic cells as men age. While its loss in blood cells has been documented and correlated with health risks, the consequences of Y chromosome loss in cancer cells and immune cells within tumors have remained poorly understood. The Cedars-Sinai investigators have now illuminated the complex interplay between Y chromosome presence, tumor progression, and immune competence, demonstrating that its concurrent loss in both tumor and immune cells creates a tumor microenvironment conducive to cancer proliferation and immune evasion.

Previous research from Cedars-Sinai had established that bladder cancer cells lacking the Y chromosome could effectively escape immune surveillance, facilitating unchecked tumor growth. Intriguingly, these Y chromosome-deficient tumors also displayed a paradoxical increased sensitivity to immune checkpoint blockade therapy, which reinvigorates the immune system’s attack against cancer. Building on these insights, the current study, led by Dr. Simon Knott and Dr. Dan Theodorescu, expanded the investigation to encompass multiple cancer types using extensive publicly available genomic and transcriptomic datasets.

Unexpectedly, the researchers discovered that the loss of the Y chromosome was not confined to cancerous epithelial cells but was also prominently present in immune cells infiltrating the tumor. This finding was particularly striking; tumors displaying Y chromosome loss in both compartments—cancer cells and immune cells—were strongly associated with highly aggressive tumor phenotypes and poor patient survival. This dual loss appears to compromise the immune system’s ability to mount an effective anti-tumor response, allowing malignant cells to thrive and spread more rapidly.

Delving deeper into the mechanisms, the scientists hypothesized that Y chromosome loss in tumor-infiltrating immune cells, such as T lymphocytes, impairs their functional capabilities. T cells are critical components of the adaptive immune system, responsible for recognizing and killing cancer cells. Loss of sex chromosome genes in T cells may disrupt normal immune signaling pathways, leading to diminished cytotoxic activity and failure to contain the tumor’s growth. This immune malfunction dovetails with the increased malignancy of cancer cells likewise missing the Y chromosome, resulting in a potent combination that undermines effective tumor control.

To validate their computational analyses, the investigators employed orthogonal methods, including fluorescence in situ hybridization and single-cell sequencing of patient tumor samples, confirming the concurrent absence of the Y chromosome in both tumor and immune cells. Moreover, preclinical models further substantiated these observations, demonstrating that tumors with this chromosomal alteration exhibited accelerated progression and resistance to conventional therapies, underscoring the clinical relevance of the findings.

One of the most transformative implications of this work lies in its potential impact on cancer immunotherapy, particularly T-cell-based treatments such as adoptive cell transfer therapies. These therapies involve harvesting T cells from patients, genetically or chemically modifying them to enhance anti-tumor efficacy, and reinfusing them to combat the cancer. The study posits that T-cell products derived from cells lacking the Y chromosome may be intrinsically less effective, raising a crucial question about current manufacturing practices and patient selection in these therapies.

Dr. Knott emphasized the need for incorporating screening protocols to detect Y chromosome status in T-cell therapies prior to infusion. This precaution could ensure that only robust, Y chromosome-intact T cells are utilized, thereby improving therapeutic success rates. Additionally, recognizing the prevalence of Y chromosome loss among older men—who represent a substantial proportion of cancer patients—this work calls for personalized approaches that account for chromosomal mosaicism in immune and tumor cells.

The study also stimulates fascinating questions about the biological underpinnings of Y chromosome loss. Unlike mutations or deletions in oncogenes and tumor suppressor genes, the disappearance of an entire chromosome is a relatively overlooked but impactful alteration. Understanding why the Y chromosome is lost in these distinct cell populations within tumors, and how this loss mechanistically alters cellular function at the molecular level, will be essential for developing targeted interventions and improving precision oncology paradigms.

Beyond direct therapeutic considerations, these discoveries shine a spotlight on the intersection of aging, sex chromosome biology, and cancer. With aging known to increase the prevalence of mosaic loss of the Y chromosome in hematopoietic and other tissues, this phenomenon might underlie the heightened cancer risk and poorer prognoses observed in elderly male patients. It also raises the prospect that restoration or compensation for Y chromosome gene function could emerge as a novel therapeutic avenue.

Dr. Robert Figlin, interim director of Cedars-Sinai Cancer, highlighted the significance of these findings within the broader landscape of precision medicine. Tailoring cancer treatment not only to molecular mutations but also to chromosomal and sex-specific factors represents an important stride in addressing the heterogeneity of cancer and improving outcomes. Ongoing research efforts are now focused on elucidating how best to integrate Y chromosome status into clinical diagnostics and how to design therapies that effectively counteract the detrimental effects of its loss.

In conclusion, the Cedars-Sinai team’s research represents a milestone in cancer biology, revealing that the concurrent loss of the Y chromosome in both malignant and immune cells fosters a tumor microenvironment that facilitates aggressive disease and undermines immune defense. This dual chromosomal loss compromises T-cell function and correlates with poor patient outcomes across multiple cancer types. By alerting the medical and research communities to the importance of Y chromosome integrity, especially in the context of immunotherapies, these findings pave the way for refined diagnostic tools and personalized treatment approaches that could significantly benefit male cancer patients worldwide.

Subject of Research:
Loss of the Y chromosome in cancer and immune cells and its impact on cancer progression and immunotherapy effectiveness

Article Title:
Concurrent loss of the Y chromosome in cancer and T cells impacts outcome

News Publication Date:
4-Jun-2025

Web References:
http://dx.doi.org/10.1038/s41586-025-09071-2

References:
Cedars-Sinai researchers, Nature, DOI: 10.1038/s41586-025-09071-2

Keywords:
Cancer cells, Cancer research, Y chromosome loss, Tumor microenvironment, Immune cells, T cells, Immunotherapy, Precision medicine, Aging, Male cancer patients